Two drug molecules achieve myelin repair in MS disease models — 2026-05-27

## Short Segments Seabird eggs show a 70% drop in forever chemicals, highlighting regulatory success. Scientists have observed a significant decrease in PFAS levels in seabird eggs over the past 55 years. These chemicals, known for their persistence in the environment, peaked in the 1990s but have since declined due to regulatory measures in North America. This drop offers strong evidence that regulation can effectively reduce environmental contamination. The study, published in the Journal of Applied Toxicology, focused on northern gannet eggs in Canada, where PFOS was the main contaminant. The findings underscore the impact of policy in addressing environmental challenges. Denver's newest clean energy source will be sewage. In an innovative move to cut greenhouse gas emissions, Denver is piloting a thermal energy network that uses heat from the city's sewage system to warm and cool buildings. This initiative is part of Denver's goal to reach net-zero emissions by 2040. The system circulates water through a loop, drawing heat from sewage to regulate building temperatures. This approach not only reduces reliance on fossil fuels but also showcases a creative solution to urban energy challenges. As cities worldwide seek sustainable energy solutions, Denver's project could serve as a model for others. ## Feature Story Two drug molecules achieve myelin repair in MS disease models, offering new hope for treatment. Researchers at the University of Helsinki have identified two compounds, K102 and K110, that successfully promote myelin regrowth in multiple sclerosis (MS) models. This breakthrough is significant because MS affects approximately three million people globally, causing the immune system to attack the myelin sheath around nerve fibers. Current treatments focus on reducing inflammation but do not repair existing damage. The identified compounds not only trigger remyelination but also reduce neuroinflammation and cross the blood-brain barrier in laboratory animals. Remyelination is crucial as it restores the protective insulation around nerve fibers, allowing efficient signal transmission in the nervous system. The compounds work through different mechanisms yet produce similar results, marking a potential shift in MS treatment strategies. The lead compound, K102, also balances immune function, which is key for long-term neurological recovery. These findings are promising for translating into human therapies, with Cadenza Bio developing the compounds further. While previous remyelination drug candidates have failed, this discovery offers a new path forward. If successful in human trials, these compounds could reverse nerve damage rather than merely slowing disease progression. This development could significantly improve the quality of life for those living with MS, providing a tangible step toward effective treatment. As research continues, the focus will be on clinical trials to confirm these results in humans, potentially transforming MS management in the future.